Evommune, Inc., a clinical-stage biotechnology firm based in Palo Alto that is exploring for new ways to treat immune-mediated inflammatory diseases, declared it has forayed into a definitive, worldwide license agreement with AprilBio Co., Ltd...
PharmaEssentia USA Corporation, a worldwide biopharmaceutical trailblazer situated in Taiwan utilizing profound mastery and demonstrated scientific principles to convey new biologics in hematology, oncology and immunology, declared completion of...
Roche, a leading Pharmaceutical firm, declared that the European Commission has given marketing authorisation for Ocrevus (ocrelizumab) subcutaneous (SC) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple...
Eli Lilly and Company has declared a collaboration with OpenAI, which will allow Lilly to use OpenAI's generative AI to develop novel antimicrobials for drug-resistant diseases. Antimicrobial resistance (AMR) is a major danger to public health...
Allecra Therapeutics and Acino declared the signing of a licensing agreement in which Acino acquire privileges to popularize Allecra's anti-microbial medication Exblifep (cefepime/enmetazobactam) within the Republic of South Africa and the member...
GSK plc, a biotechnology company, reported that Japan's Ministry of Health, Labour and Welfare (MHLW) has endorsed Omjjara (momelotinib) for the treatment of myelofibrosis. Omjjara is an oral, once-daily inhibitor of JAK1/JAK2 and the activin A...
Roche, a leading biotechnology firm, declared the availability of its new analytical units, the cobas c 703 and cobas ISE neo, for the cobas pro integrated solutions, in nations accepting the CE mark. The cobas c 703 and cobas ISE neo logical...
The International Society on Thrombosis and Haemostasis (ISTH), the most prominent international professional medical-scientific organization committed to improving the understanding, prevention, diagnosis, and treatment of thrombotic and...
Alivexis, Inc. furthermore, Melodia Therapeutics AG, an organization set up by Forty51 Endeavors, declared that they have forayed into an exclusive license agreement for the overall development, assembling, and commercialization of Alivexis...
Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical firm with headquarters in Switzerland dedicated to treating patients with severe bacterial and fungal infections, declared that it has forayed into an asset purchase agreement...
, CDSCO.jpg)
